(Q46982869)

27 December 2017

title

High-dose enzyme replacement therapy attenuates cerebroventriculomegaly in a mouse model of mucopolysaccharidosis type II. (English)

1 reference

27 December 2017

enzyme replacement therapy

main subject

0 references

author name string

So Yoon Ahn

1

1 reference

27 December 2017

Yun Sil Chang

2

1 reference

27 December 2017

Dong Kyung Sung

3

1 reference

27 December 2017

Ah-Ra Ko

4

1 reference

27 December 2017

Chi Hwa Kim

5

1 reference

27 December 2017

Dong Kyeom Yoo

6

1 reference

27 December 2017

Keun Ho Lim

7

1 reference

27 December 2017

Young Bae Sohn

8

1 reference

27 December 2017

Dong Kyu Jin

9

1 reference

27 December 2017

Won Soon Park

10

1 reference

27 December 2017

publication date

5 September 2013

1 reference

27 December 2017

Journal of Human Genetics

published in

1 reference

27 December 2017

volume

58

1 reference

27 December 2017

issue

11

1 reference

27 December 2017

page(s)

728-733

1 reference

27 December 2017

https://scigraph.springernature.com/pub.10.1038/jhg.2013.92

exact match

0 references

cites work

Recognition and diagnosis of mucopolysaccharidosis II (Hunter syndrome).

1 reference

https://api.crossref.org/works/10.1038%2FJHG.2013.92

Characterization of a novel mucopolysaccharidosis type II mouse model and recombinant AAV2/8 vector-mediated gene therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJHG.2013.92

Changes in glycogen and glycosaminoglycan levels in hepatocytes of iduronate-2-sulfatase knockout mice before and after recombinant iduronate-2-sulfatase supplementation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJHG.2013.92

Auditory characteristics and therapeutic effects of enzyme replacement in mouse model of the mucopolysaccharidosis (MPS) II.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJHG.2013.92

Natural progression of neurological disease in mucopolysaccharidosis type II.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJHG.2013.92

A phase II/III clinical study of enzyme replacement therapy with idursulfase in mucopolysaccharidosis II (Hunter syndrome)

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJHG.2013.92

Treatment reduces or stabilizes brain imaging abnormalities in patients with MPS I and II.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJHG.2013.92

Enzyme replacement therapy (ERT) procedure for mucopolysaccharidosis type II (MPS II) by intraventricular administration (IVA) in murine MPS II.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJHG.2013.92

Correction of CNS defects in the MPSII mouse model via systemic enzyme replacement therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJHG.2013.92

Correlation of automated volumetric analysis of brain MR imaging with cognitive impairment in a natural history study of mucopolysaccharidosis II.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJHG.2013.92

Overcoming the blood-brain barrier with high-dose enzyme replacement therapy in murine mucopolysaccharidosis VII.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJHG.2013.92

The characterization of a murine model of mucopolysaccharidosis II (Hunter syndrome).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJHG.2013.92

IDS crossing of the blood-brain barrier corrects CNS defects in MPSII mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJHG.2013.92

Improvement of CNS defects via continuous intrathecal enzyme replacement by osmotic pump in mucopolysaccharidosis type II mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJHG.2013.92

Preclinical dose ranging studies for enzyme replacement therapy with idursulfase in a knock-out mouse model of MPS II

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJHG.2013.92

Idursulfase in Hunter syndrome treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJHG.2013.92

Otologic manifestations of Hunter syndrome and their relationship with speech development

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJHG.2013.92

inferred from DOI database lookup

7 January 2021

based on heuristic

The efficiency of systematic sampling in stereology and its prediction.

1 reference

https://api.crossref.org/works/10.1038%2FJHG.2013.92

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1038/JHG.2013.92

1 reference

27 December 2017

PubMed ID

24005894

1 reference

27 December 2017